Posts Tagged ‘lung cancer’

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…

Read More

Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Personalized Medicine for Small Cell Lung Cancer SOMERVILLE, Mass.— January 29, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018. The conference will focus…

Read More

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —January 8, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of…

Read More

Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA

Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…

Read More

Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market

Tozaride has demonstrated clinical effectiveness in treating lung cancer SOMERVILLE, Mass.— September 6, 2017— Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights…

Read More

Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting

  Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO)…

Read More

Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study

Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…

Read More

Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling

Andarix’ R&D expands to include Notch Influencing Molecules   ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…

Read More